Physician profile
Melissa Smith
NPI 1922198621
$2,590.57
in general payments reported to CMS, 2019-2025
14 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $135 · 2021: $212 · 2022: $261 · 2023: $502 · 2024: $815 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,856.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.77 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Biotissue Holdings INC. | $519.85 | 2023-2025 | |
| Allergan, INC. | $248.85 | 2020-2021 | |
| Alcon Vision LLC | $246.77 | 2021-2025 | Tryptyr, Rocklatan, Eysuvis |
| Rxsight INC | $188.38 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $158.51 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $130.04 | 2024-2025 | Xdemvy |
| Amgen INC. | $100.56 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $77.35 | 2023-2024 | Vyzulta, Miebo |
| Oyster Point Pharma, INC. | $67.85 | 2022-2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $22.90 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Eyevance Pharmaceuticals LLC | $14.71 | 2022 | |
| Horizon Therapeutics Plc | $13.49 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.